Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$6.83
+1.5%
$7.17
$2.32
$10.13
$364.04M2.47954,870 shs1.01 million shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$2.00
-2.0%
$1.41
$0.66
$2.18
$463.70M1.952.78 million shs2.69 million shs
Procaps Group S.A. stock logo
PROC
Procaps Group
$0.95
-40.3%
$0.95
$0.50
$3.78
$107.18M-0.0560,897 shs658,169 shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$36.55
-0.1%
$27.01
$11.17
$40.50
$404.42M-0.02173,996 shs56,129 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+1.49%-12.55%-1.44%+21.53%-26.40%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-1.96%+8.70%+65.29%+69.49%+121.41%
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00%0.00%0.00%0.00%-58.70%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-0.08%-5.36%+53.38%+49.43%+3,654,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.2635 of 5 stars
3.33.00.00.01.92.50.0
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.9158 of 5 stars
3.51.00.04.73.81.70.0
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2.6884 of 5 stars
3.60.00.00.02.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.63
Moderate Buy$7.5710.86% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$8.25312.50% Upside
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00
N/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.11
Buy$47.5029.96% Upside

Current Analyst Ratings Breakdown

Latest PROC, PVLA, FULC, and GOSS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.00
7/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00 ➝ $12.00
7/21/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$56.00
7/14/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$11.00
5/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.00
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
5/16/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$53.00 ➝ $52.00
5/15/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$10.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M4.62N/AN/A$3.96 per share1.72
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$114.70M3.96N/AN/A$0.13 per share15.38
Procaps Group S.A. stock logo
PROC
Procaps Group
$409.92M0.26N/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M9.44N/AN/A$5.58 per share6.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%N/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)
Procaps Group S.A. stock logo
PROC
Procaps Group
$42.54MN/A0.00N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)

Latest PROC, PVLA, FULC, and GOSS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$0.81N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18N/AN/AN/A$4.12 millionN/A
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
5/15/2025Q1 2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$3.40-$0.74+$2.66-$0.74N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
28.71
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70
5.71
5.71
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
8.84
8.84

Institutional Ownership

CompanyInstitutional Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Procaps Group S.A. stock logo
PROC
Procaps Group
N/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%

Insider Ownership

CompanyInsider Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
Procaps Group S.A. stock logo
PROC
Procaps Group
19.90%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
20.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.30 million212.07 millionOptionable
Procaps Group S.A. stock logo
PROC
Procaps Group
4,900112.82 million90.37 millionNot Optionable
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A11.06 million8.79 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$6.83 +0.10 (+1.49%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.84 +0.00 (+0.07%)
As of 08/1/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$2.00 -0.04 (-1.96%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.00 0.00 (-0.25%)
As of 08/1/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Procaps Group stock logo

Procaps Group NASDAQ:PROC

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$36.55 -0.03 (-0.08%)
As of 08/1/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.